Skip to main content
Premium Trial:

Request an Annual Quote

European Regulators Clear Danaher Purchase of Beckman Coulter

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher's pending $6.8 billion purchase of Beckman Coulter has cleared the last regulatory hurdle, the Washington-based conglomerate announced after the close of the market Thursday.

The European Commission approved the deal, paving the way for the acquisition to close. Danaher's tender offer to acquire all outstanding shares of Beckman Coulter stock at $83.50 per share is scheduled to expire at 5 p.m. EDT, June 24. It reiterated that the deal is expected to be completed by the end of the month. The US Federal Trade Commission cleared the purchase in March.

Earlier this week, Danaher announced a public offering at $51.75 per share to raise as much as $965.3 million in net proceeds if underwriters on the offering exercise their over-allotment option in full. Net proceeds will be used to pay a portion of the acquisition. Proceeds also may be used for general corporate purposes, if there are any remaining from the offering or if the Beckman deal fails to close.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.